Drugs.com - Monthly Update April 2026

In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments.Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed.Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.Chapters:(00:21) - Intro (01:05) - Foundayo (01:59) - Otarmeni (02:55) - Idvynso (03:50) - Langlara (04:42) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app